Shade Lines of Curved Surfaces - Rotational and Helical Circular Surfaces

Uobičajeno je da se tangenta t na rastavnicu e oble plohe Φ konstruira na temelju činjnice da su t i zraka svjetlosti l par konjugiranih dijametara tzv. DUPINOVE indikatrise u promatranoj točki P. Ovaj rad opisuje drukčiji pristup konstrukciji takve tangente: rastavnica e definira se kao prodorna krivulja plohe Φ i specijalne pravčaste plohe Ψ koja ovisi o Φ i snopu zraka svjetlosti. Ψ se uvodi kao pridružena pravčasta ploha duž krivulje e. Taj pristup omogućuje jednostavnu, linearno i globalno primjenjivu konstrukciju tangente t za rotacijske i zavojne plohe, na način nacrtne geometrije. Metoda je također prikladna za klizne plohe isto kao i za centralnu rasvjetu. U nekim je slučajevima ploha Ψ pravčasta kvartika.Typically a tangent t to the shade line e of a curved surface Φ is constructed by making use of the fact that t and the light ray l form a pair of conjugate diameters of the so-called DUPIN-indicatix of Φ at an investigated point P. This article describes a very different approach to developing such a tangent: The shade line e is defined as the intersection of Φ and a special ruled surface Ψ, which depends both on Φ and on the bundle of light rays. Ψ is introduced as accompanying ruled surface along e. This approach allows a simple, linear and globally applicable construction of t for rotational and helical surfaces by means of descriptive geometry. The method is also suitable for translation surfaces as well as for central illumination [4]. In a few cases Ψ is a ruled quartic

Shade Lines of Curved Surfaces - Linear Approach to Involution of Conjugate Tangents at Points of Translation Surfaces

U časopisu KoG 6 dana je konstrukcija tangenata rastavnice oblih ploha metodom ploha pratilica i njena primjena na rotacijske i zavojne plohe. U ovom radu ta se metoda proširuje i na klizne plohe. U onim točkama plohe za koje su poznate zakrivljenosti samo dviju konjugiranih tangenata postignuta je ograničena linearna konstrukcija involucije konjugiranih tangenata plohe. Na kraju rada razmatra se kružno raslojena zavojna ploha kao klizna ploha, čime se postižu daljnje elegantne konstrukcije tangenata. Opisani su i posebni slučajevi ove metode pri centralnoj rasvjeti. Daljnje pojedinosti o ovoj temi opisane su u [4].In KoG 6 we introduced a global approach to the tangents of the shade lines of curved surfaces. The constructions are made by using an accompanying ruled surface along the shade line. In this paper the method is expanded to translation surfaces. In that way we get a linear access to the involution of conjugate tangents in those points of a surface where the curvature at two conjugate tangents is given. At the end of the paper a helical surface with circular cross section is handled as translation surface, which leads to additional elegant constructions for the tangents of its shade line. For more details on the general subject see [4]

A Different Kind of Relapse: Ethanol as an Additive in Chemotherapy Formulations

Some chemotherapy formulations contain ethanol as a solvent which can become relevant for medical and nonmedical reasons. Only a few studies have tried to quantify the effects of ethanol in chemotherapy preparations. Furthermore, the alcohol amount highly depends on the specific formulation, with some variation among different manufacturers. Although the actual increase in blood alcohol levels after ethanol-based chemotherapies seems to be limited, the FDA recently released a warning that docetaxel may cause symptoms of alcohol intoxication. Here, we report on a patient with breast cancer who experienced a relapse of alcohol abuse after a single docetaxel infusion. We hypothesize a causal relationship with the ethanol-containing docetaxel infusion. Today, no guidelines exist for the use of ethanol-based chemotherapy, and patient consent forms do not address this matter. We conclude that physicians prescribing chemotherapy and patients should be aware of the potential risks of ethanol-containing infusions and nonethanol- based alternatives should be discussed when needed or desired by the patient. This could be facilitated by revised patient consent forms

Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View

Gastric cancer is a leading cause of cancer death worldwide. Systemic treatment comprising chemotherapy and targeted therapy is the standard of care in advanced/metastatic gastric cancer. Comprehensive molecular characterization of gastric adenocarcinomas by the TCGA Consortium and ACRG has resulted in the definition of distinct molecular subtypes. These efforts have in parallel built a basis for the development of novel molecularly stratified treatment approaches. Based on this molecular characterization, an increasing number of specific genomic alterations can potentially serve as treatment targets. Consequently, the development of promising compounds is ongoing. In this review, key molecular alterations in gastric and gastroesophageal junction cancers will be addressed. Finally, the current status of the translation of targeted therapy towards clinical applications will be reviewed

Deutsch-jüdische Bibliografie – Digital, vernetzt und erforschbar?

Der Beitrag widmet sich dem Feld der deutsch-jüdischen Bibliografie. Eine in technischer Hinsicht zeitgemäß angelegte fachspezifische Bibliografie kann den heutigen Nutzererwartungen entsprechen, wenn sie - digital und strukturiert (als Datenbank) angeboten wird, - maschinenlesbare Schnittstellen (und/oder einen Download) anbietet, - unter einer freien, möglichst offenen Lizenz steht und - sich an Standards und Normdaten orientiert. Entsprechend organisierte Bibliografien lassen sie sich aggregieren, vernetzen und als Forschungsdaten nutzen

Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer – the multinational MATEO study

Background: The optimal duration of firstline chemotherapy in metastatic esophagogastric cancer is unknown. In most clinical trials therapy was given until tumour progression or limiting toxicity. Maintenance concepts aiming to prolong the duration of response and maintain quality of life have been established in other tumour types but not in esophagogastric cancer. S-1 is an oral fluoropyrimidine with proven efficacy in metastatic esophagogastric cancer. Methods: The Maintenance Teysuno® (S-1) in esophagogastric cancer (MATEO) trial is a multinational, randomized phase II study that explores the role of S-1 maintenance therapy in Her-2 negative, advanced esophagogastric adenocarcinoma. After a 12-week firstline platinum-fluoropyrimidine-based chemotherapy patients without tumour progression are randomized in a 2:1 allocation to receive S-1 alone or continue with the same regimen as during the primary period. The primary endpoint is overall survival. Secondary endpoints include safety and toxicity, progression-free survival and quality of life. Correlative biomarker analyses focus on the identification of a subgroup of patients with a prolonged benefit from S-1 based maintenance therapy. Discussion: MATEO will be the first trial to define the role of a S-1 based maintenance therapy in patients having received a platinum-based firstline chemotherapy. Trial registration: NCT02128243 (date of registration: 29–04-2014)

Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multicenter, Phase I/II Trial

Background: Peritoneal carcinomatosis (PC) is common in gastrointestinal (GI) cancer and there is no effective standard treatment. We investigated the tolerability and maximum tolerated dose (MTD) of the trifunctional antibody catumaxomab in patients with PC. Methods: In this open-label, phase I/II clinical trial, patients with epithelial cell adhesion molecule (EpCAM)-positive PC from GI cancer received 4 sequential intraperitoneal catumaxomab infusions: day 0: 10 mu g; day 3: 10 or 20 mu g; day 7: 30, 50, or 100 mu g; and day 10: 50, 100, or 200 mu g. Dose escalation was guided by dose-limiting toxicities. Results: The MTD was 10, 20, 50, and 200 mu g on days 0, 3, 7, and 10, respectively. Catumaxomab had an acceptable safety profile: Most common treatment-related adverse events (at the MTD) were fever, vomiting, and abdominal pain. At final examination, 11/17 evaluable patients (65%) were progression free: 1 patient had a complete and 3 a partial response. Median overall survival from the time of diagnosis of PC was 502 days. Conclusions: Intraperitoneal catumaxomab is a promising option for the treatment of PC from GI cancer